Calcipotriol Anhydrous vs Monohydrate: Which Form Should Your Formulation Team Source?

By Team DK Pharmachem October 01, 2026

Calcipotriol Anhydrous vs Monohydrate: Which Form Should Your Formulation Team Source?

A purchase order for “Calcipotriol” looks simple. It is not. The same molecule is sold in two solid forms, anhydrous and monohydrate, and the choice affects potency calculations, stability behaviour, regulatory filings and supplier shortlisting.

Teams that treat the two forms as interchangeable usually find out during a stability study, a dossier review or an assay reconciliation. This guide helps your formulation, regulatory and procurement teams make the decision before the first purchase order.

Key Takeaways

• Calcipotriol Anhydrous (CAS 112965-21-6) and Calcipotriol Monohydrate (CAS 147657-22-5) are the same active moiety in different solid forms.
• The monohydrate carries one molecule of water per molecule of calcipotriol, so its molecular weight is higher (430.62 g/mol versus 412.61 g/mol). Potency calculations must account for this.
• Documentation differs by form. A supplier’s regulatory package for one form does not automatically apply to the other.
• Neither form is “better” in general. The right choice depends on your reference product, your dosage form and the market you are filing in.
• Confirm the form at the specification stage, not at the purchase order stage.

What is Calcipotriol, and Why does the form matter?

Calcipotriol (known as calcipotriene in the United States) is a synthetic Vitamin D3 analogue used in topical treatment of plaque psoriasis. It slows excessive skin cell growth and supports normal cell differentiation. It appears in ointments, creams, scalp solutions and foams, often combined with a corticosteroid.

Potency in finished products is typically measured in micrograms per gram. At that scale, small differences in the active’s composition, such as water content, translate directly into dosing accuracy. That is why the solid form is a specification decision and not a labelling detail.

Calcipotriol Anhydrous vs Monohydrate at a Glance

Parameter	Calcipotriol Anhydrous	Calcipotriol Monohydrate
CAS number	112965-21-6	147657-22-5
Molecular formula	C27H40O3	C27H40O3·H2O
Molecular weight	412.61 g/mol	430.62 g/mol
Water in crystal lattice	None	One water molecule per molecule
Appearance (DK PharmaChem)	White crystalline powder	White crystalline powder
Purity (DK PharmaChem)	99% or higher	99% or higher
Therapeutic use	Topical psoriasis therapy	Topical psoriasis therapy

The therapeutic activity is the same. The practical differences sit in handling, documentation and calculation.

Five factors that should drive your sourcing decision

1. Potency Correction and Assay Basis

This is the most common source of error. The monohydrate contains about 4 percent water by weight, so one gram of monohydrate delivers roughly 0.96 g of anhydrous-equivalent active. The ratio is simply 412.61 divided by 430.62.

When you switch forms, or compare quotes for the two, check:

• Whether the assay is stated on the “as is” basis or the “anhydrous” basis
• Whether your batch manufacturing record applies a potency correction factor
• Whether your reference product’s label claim refers to the anhydrous or hydrated form

A mismatch here can shift your finished product’s strength even though both ingredients are “99% pure”.

2. Solid-State Behaviour and Stability

Calcipotriol is sensitive to light, heat and oxidation, and the crystalline form influences how it behaves in storage and in your process. A defined hydrate can offer a more predictable solid form, while an anhydrous material needs attention to moisture exposure during handling and storage.

Your own compatibility and stability data should settle this. Ask each candidate supplier for:

• Storage and shelf-life guidance on the Certificate of Analysis (CoA)
• Water content results by batch
• Packaging details that protect against light and moisture

3. Regulatory Documentation Pathway

Documentation is where the two forms diverge most for buyers, and it is the point most often overlooked. Drug Master File (DMF), Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM), and Open Drug Master File (ODMF) coverage are typically tied to a specific form from a specific manufacturing site.

On DK PharmaChem’s Vitamin D3 category page, the documentation listed for Calcipotriol Anhydrous is a Tech Pack, while Calcipotriol Monohydrate is listed with CEP (EDQM) and ODMF. If your filing needs a CEP reference, that difference can decide the form before any technical preference does.

Always confirm, in writing, which document applies to which form and which market.

4. Pharmacopoeial Alignment

Pharmacopoeial monographs are written for specific forms and can carry different identification tests, water content limits and assay definitions. Check that the form you order matches the monograph named in your dossier. If your target market requires a particular pharmacopoeia, ask the supplier to confirm the grade for that exact form before sampling.

5. Formulation Fit and Reference Product Alignment

Match the form to your reference listed drug and your dosage form. Ointment bases, aqueous creams and scalp solutions stress the active differently. Generic developers should also check which form the originator’s documentation describes, since consistency with the reference product simplifies comparability arguments.

When does each form make sense?

Calcipotriol Anhydrous may suit teams that:

• Work to a reference product or internal method defined on the anhydrous basis
• Have an established process and stability data built on the anhydrous form
• Do not require a CEP reference for their filing

Calcipotriol Monohydrate may suit teams that:

• Need a CEP-backed documentation route for European submissions
• Prefer a defined hydrate as a more predictable solid form for handling
• Are developing a generic psoriasis product where monohydrate is the established choice in their market

These are starting points, not rules. Your formulation data and your regulatory strategy should have the final say.

A Supplier Qualification Checklist for Calcipotriol

Before you approve a source for either form, ask for:

• A CoA for recent batches, including assay basis and water content
• The documentation available for that specific form and for your destination market
• Pharmacopoeial grade confirmation for that specific form
• Impurity profile and residual solvent data
• Stability data and recommended storage conditions
• Packaging specification, including light and moisture protection
• Manufacturing site details and Good Manufacturing Practice (GMP) certification
• Change control and notification commitments
• Sample availability and lead times for trial batches

How DK PharmaChem Supports Calcipotriol Buyers

DK PharmaChem is a WHO-GMP certified manufacturer based in India, operating since 1980, and supplies both forms as part of its Vitamin D3 analogues range. Both are offered as white crystalline powder at 99% purity or higher, with a CoA per batch and packing in HDPE or fibre drums. Buyers can review the Calcipotriol Anhydrous and Calcipotriol Monohydrate specifications, or see the full Vitamin D3 analogues range alongside Alfacalcidol and Calcitriol.

Frequently Asked Questions

What is the difference between Calcipotriol Anhydrous and Calcipotriol Monohydrate?

Both contain the same active moiety. Calcipotriol Monohydrate includes one water molecule in its crystal structure, giving it a molecular weight of 430.62 g/mol, while the anhydrous form has none and weighs 412.61 g/mol. This difference affects potency calculations, documentation and handling.

Do I need a potency correction when switching from anhydrous to monohydrate?

Usually yes. Because the monohydrate contains about 4 percent water by weight, you need roughly 4 percent more material to deliver the same amount of active. Confirm whether the supplier’s assay is stated on an as-is or anhydrous basis before adjusting your batch records.

Which form is better for psoriasis formulations?

Neither is universally better, since both serve topical psoriasis therapy. The right choice depends on your reference product, your dosage form, your stability data and the regulatory documentation your target market requires.

Are the regulatory documents the same for both forms?

Not necessarily. Documentation such as a Drug Master File, a Certificate of Suitability or a Tech Pack is typically specific to a form and a manufacturing site. Ask the supplier to confirm in writing which documents apply to the exact form you plan to buy.

What should I ask a supplier before ordering Calcipotriol?

Request recent batch CoAs with assay basis and water content, the documentation available for your destination market, pharmacopoeial grade confirmation, impurity data, stability and storage guidance, and packaging details.

Can DK PharmaChem supply both Calcipotriol forms?

Yes. DK PharmaChem manufactures both Calcipotriol Anhydrous and Calcipotriol Monohydrate in India under WHO-GMP certified conditions. Share your target form, pharmacopoeial standard and destination country to receive a tailored quote.

Conclusion

The anhydrous versus monohydrate decision is a specification, regulatory and calculation decision, so make it early and in writing. Start with your reference product and target market, check the potency basis, and confirm which documents come with each form. A short technical conversation with your supplier now can save months of rework later.

Planning a Calcipotriol sourcing project? Contact the DK PharmaChem team with your required form, pharmacopoeial standard and destination market for a tailored quote and documentation overview.